UnitedHealth Group (UNH) is undergoing a severe market test. Over the past 12 months, its stock price has lost nearly half of its market value. Entering 2026, the stock has continued its decline, dropping 13% cumulatively by the end of January, following a steep 35% plunge throughout 2025. Investors are selling off, and market concerns persist.
The company’s latest quarterly results, released recently, have further heightened doubts about its future prospects. Although the fourth-quarter adjusted earnings per share of $2.11 slightly exceeded analysts’ expectations of $2.10, revenue was only $113.2 billion, falling short of Wall Street’s estimate of $113.82 billion. More unsettling for the market is the company’s revenue guidance for 2026, which is approximately $439 billion, representing an expected decline of 2% year over year.
A key backdrop to the current stock price pressure is the changing policy environment. The Trump administration recently proposed keeping the Medicare Advantage rates for 2027 essentially unchanged, with only a marginal increase of 0.09%, far below the analysts’ previous expectation of at least a 4% rise. If implemented, this policy would significantly impact UnitedHealth and other health insurance companies. It is worth noting that the final Medicare and Medicaid Services (CMS) rate plan is expected to be determined this spring. Julie Utterback, a stock research analyst at Morningstar, noted, “CMS has hinted that the final rate may be increased by 2.5% compared to the initial draft, as the anticipated billing trends have not yet been incorporated.”
Beyond policy pressures, UnitedHealth also faces structural challenges such as rising healthcare utilization and increasing medical costs. The robust performance driven by both revenue and profit growth for years may be difficult to sustain in the short term. CEO Stephen Hemsley stated during the fourth-quarter earnings call that, while he cannot specifically forecast the situation for 2027, he believes the company can still achieve a long-term growth rate of 13% to 16%.
Looking ahead, prior to the CMS proposal, UnitedHealth had projected relatively moderate growth for 2026, low double-digit earnings growth for 2027, and a return to historical growth levels by 2028. Despite the challenging short-term outlook, if the company can deliver on its long-term growth commitments, the deeply discounted stock price after the recent sharp decline may offer potential opportunities for long-term investors.
